FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray

Thumbnail
2017
2866.pdf (120.9Kb)
Authors
Perić, Aleksandar
Vezmar-Kovačević, Sandra
Gacesa, Dejan
Perić, Aneta
Article (Published version)
Metadata
Show full item record
Abstract
Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS. Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 mu g twice daily for 7 days. Group 2 (n=23) received only MFNS 200 mu g twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Si...gnificant improvement of all clinical parameters was found after both treatment modalities (p lt 0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.

Keywords:
Glucocorticoids / inflammation / medicinal plants / rhinitis / sinusitis
Source:
ENT Updates, 2017, 7, 2, 68-74
Publisher:
  • Deomed Publ, Istanbul, Istanbul

DOI: 10.2399/jmu.2017002003

ISSN: 2149-7109

WoS: 000413402500003

[ Google Scholar ]
1
URI
http://farfar.pharmacy.bg.ac.rs/handle/123456789/2868
Collections
  • Radovi istraživača / Researchers’ publications
Institution
Pharmacy
TY  - JOUR
AU  - Perić, Aleksandar
AU  - Vezmar-Kovačević, Sandra
AU  - Gacesa, Dejan
AU  - Perić, Aneta
PY  - 2017
UR  - http://farfar.pharmacy.bg.ac.rs/handle/123456789/2868
AB  - Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS. Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 mu g twice daily for 7 days. Group 2 (n=23) received only MFNS 200 mu g twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Significant improvement of all clinical parameters was found after both treatment modalities (p lt 0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.
PB  - Deomed Publ, Istanbul, Istanbul
T2  - ENT Updates
T1  - Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray
VL  - 7
IS  - 2
SP  - 68
EP  - 74
DO  - 10.2399/jmu.2017002003
ER  - 
@article{
author = "Perić, Aleksandar and Vezmar-Kovačević, Sandra and Gacesa, Dejan and Perić, Aneta",
year = "2017",
url = "http://farfar.pharmacy.bg.ac.rs/handle/123456789/2868",
abstract = "Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS. Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 mu g twice daily for 7 days. Group 2 (n=23) received only MFNS 200 mu g twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Significant improvement of all clinical parameters was found after both treatment modalities (p lt 0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.",
publisher = "Deomed Publ, Istanbul, Istanbul",
journal = "ENT Updates",
title = "Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray",
volume = "7",
number = "2",
pages = "68-74",
doi = "10.2399/jmu.2017002003"
}
Perić A, Vezmar-Kovačević S, Gacesa D, Perić A. Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray. ENT Updates. 2017;7(2):68-74
Perić, A., Vezmar-Kovačević, S., Gacesa, D.,& Perić, A. (2017). Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray.
ENT UpdatesDeomed Publ, Istanbul, Istanbul., 7(2), 68-74.
https://doi.org/10.2399/jmu.2017002003
Perić Aleksandar, Vezmar-Kovačević Sandra, Gacesa Dejan, Perić Aneta, "Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray" 7, no. 2 (2017):68-74,
https://doi.org/10.2399/jmu.2017002003 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB